e-learning
resources
Paris 2018
Monday, 17.09.2018
Lung cancer: modern therapies and beyond
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis
S. Koo (Seoul, Republic of Korea), K. Kim (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea), S. Uh (Seoul, Republic of Korea)
Source:
International Congress 2018 – Lung cancer: modern therapies and beyond
Session:
Lung cancer: modern therapies and beyond
Session type:
Thematic Poster
Number:
2802
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Koo (Seoul, Republic of Korea), K. Kim (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea), S. Uh (Seoul, Republic of Korea). Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis. 2802
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
Source: Eur Respir Rev 2010 19: 186-196
Year: 2010
A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations
Source: Annual Congress 2006 - Lung cancer treatment
Year: 2006
Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival
Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Year: 2009
Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker?
Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology
Year: 2007
Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer.
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up
Source: Eur Respir J 2009; 33: 436-440
Year: 2009
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
Source: Eur Respir J 2011; 37: 624-631
Year: 2011
Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study
Source: Eur Respir J 2007; 29: 128-133
Year: 2007
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations
Source: International Congress 2015 – How to treat brain metastases
Year: 2015
A blood-based test for epidermal growth factor receptor mutations in patients with non-small cell lung cancer
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008
The results of gefitinib (Iressa) treatment in 89 patients with advanced non-small cell lung cancer (NSCLC) on expanded access programme (EAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 753s
Year: 2006
Targeting gene of insulin-like growth factor type I (IGF-I) on
in vitro
model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 387s
Year: 2006
Epidermal growth factor receptor mutation status in advanced non-small cell lung cancer: A single institution experience
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer
Source: Eur Respir J 2011; 37: 183-193
Year: 2011
Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 811s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept